Cargando…
Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biomet...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328110/ https://www.ncbi.nlm.nih.gov/pubmed/32598179 http://dx.doi.org/10.1200/CCI.20.00010 |
_version_ | 1783552681174892544 |
---|---|
author | Hasnain, Zaki Nilanon, Tanachat Li, Ming Mejia, Aaron Kolatkar, Anand Nocera, Luciano Shahabi, Cyrus Cozzens Philips, Frankie A. Lee, Jerry S.H. Hanlon, Sean E. Vaidya, Poorva Ueno, Naoto T. Yennu, Sriram Newton, Paul K. Kuhn, Peter Nieva, Jorge |
author_facet | Hasnain, Zaki Nilanon, Tanachat Li, Ming Mejia, Aaron Kolatkar, Anand Nocera, Luciano Shahabi, Cyrus Cozzens Philips, Frankie A. Lee, Jerry S.H. Hanlon, Sean E. Vaidya, Poorva Ueno, Naoto T. Yennu, Sriram Newton, Paul K. Kuhn, Peter Nieva, Jorge |
author_sort | Hasnain, Zaki |
collection | PubMed |
description | PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biometric sensor can be used during a clinic visit to identify patients who are at risk for complications, particularly unexpected hospitalizations that may delay treatment or result in low physical activity. We aim to provide a novel and objective means of predicting tolerability to chemotherapy. METHODS: Thirty-eight patients across three centers in the United States who were diagnosed with a solid tumor with plans for treatment with two cycles of highly emetogenic chemotherapy were included in this single-arm, observational prospective study. A noninvasive motion-capture system quantified patient movement from chair to table and during the get-up-and-walk test. Activity levels were recorded using a wearable sensor over a 2-month period. Changes in kinematics from two motion-capture data points pre- and post-treatment were tested for correlation with unexpected hospitalizations and physical activity levels as measured by a wearable activity sensor. RESULTS: Among 38 patients (mean age, 48.3 years; 53% female), kinematic features from chair to table were the best predictors for unexpected health care encounters (area under the curve, 0.775 ± 0.029) and physical activity (area under the curve, 0.830 ± 0.080). Chair-to-table acceleration of the nonpivoting knee (t = 3.39; P = .002) was most correlated with unexpected health care encounters. Get-up-and-walk kinematics were most correlated with physical activity, particularly the right knee acceleration (t = −2.95; P = .006) and left arm angular velocity (t = −2.4; P = .025). CONCLUSION: Chair-to-table kinematics are good predictors of unexpected hospitalizations, whereas the get-up-and-walk kinematics are good predictors of low physical activity. |
format | Online Article Text |
id | pubmed-7328110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73281102021-06-29 Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic Hasnain, Zaki Nilanon, Tanachat Li, Ming Mejia, Aaron Kolatkar, Anand Nocera, Luciano Shahabi, Cyrus Cozzens Philips, Frankie A. Lee, Jerry S.H. Hanlon, Sean E. Vaidya, Poorva Ueno, Naoto T. Yennu, Sriram Newton, Paul K. Kuhn, Peter Nieva, Jorge JCO Clin Cancer Inform Original Reports PURPOSE: Performance status (PS) is a key factor in oncologic decision making, but conventional scales used to measure PS vary among observers. Consumer-grade biometric sensors have previously been identified as objective alternatives to the assessment of PS. Here, we investigate how one such biometric sensor can be used during a clinic visit to identify patients who are at risk for complications, particularly unexpected hospitalizations that may delay treatment or result in low physical activity. We aim to provide a novel and objective means of predicting tolerability to chemotherapy. METHODS: Thirty-eight patients across three centers in the United States who were diagnosed with a solid tumor with plans for treatment with two cycles of highly emetogenic chemotherapy were included in this single-arm, observational prospective study. A noninvasive motion-capture system quantified patient movement from chair to table and during the get-up-and-walk test. Activity levels were recorded using a wearable sensor over a 2-month period. Changes in kinematics from two motion-capture data points pre- and post-treatment were tested for correlation with unexpected hospitalizations and physical activity levels as measured by a wearable activity sensor. RESULTS: Among 38 patients (mean age, 48.3 years; 53% female), kinematic features from chair to table were the best predictors for unexpected health care encounters (area under the curve, 0.775 ± 0.029) and physical activity (area under the curve, 0.830 ± 0.080). Chair-to-table acceleration of the nonpivoting knee (t = 3.39; P = .002) was most correlated with unexpected health care encounters. Get-up-and-walk kinematics were most correlated with physical activity, particularly the right knee acceleration (t = −2.95; P = .006) and left arm angular velocity (t = −2.4; P = .025). CONCLUSION: Chair-to-table kinematics are good predictors of unexpected hospitalizations, whereas the get-up-and-walk kinematics are good predictors of low physical activity. American Society of Clinical Oncology 2020-06-29 /pmc/articles/PMC7328110/ /pubmed/32598179 http://dx.doi.org/10.1200/CCI.20.00010 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Reports Hasnain, Zaki Nilanon, Tanachat Li, Ming Mejia, Aaron Kolatkar, Anand Nocera, Luciano Shahabi, Cyrus Cozzens Philips, Frankie A. Lee, Jerry S.H. Hanlon, Sean E. Vaidya, Poorva Ueno, Naoto T. Yennu, Sriram Newton, Paul K. Kuhn, Peter Nieva, Jorge Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title_full | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title_fullStr | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title_full_unstemmed | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title_short | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic |
title_sort | quantified kinematics to evaluate patient chemotherapy risks in clinic |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328110/ https://www.ncbi.nlm.nih.gov/pubmed/32598179 http://dx.doi.org/10.1200/CCI.20.00010 |
work_keys_str_mv | AT hasnainzaki quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT nilanontanachat quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT liming quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT mejiaaaron quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT kolatkaranand quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT noceraluciano quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT shahabicyrus quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT cozzensphilipsfrankiea quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT leejerrysh quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT hanlonseane quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT vaidyapoorva quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT uenonaotot quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT yennusriram quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT newtonpaulk quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT kuhnpeter quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic AT nievajorge quantifiedkinematicstoevaluatepatientchemotherapyrisksinclinic |